T-cell lymphomas (TCLs) are a malignancy characterized by tumor aggression and resistance to traditional chemotherapy. Disruption of the extrinsic cell death pathway is essential for resistance to chemotherapy. PIM1 serves as a crucial modulator in cancers. However, the role of PIM1 in TCLs remains unclear. In this study, we studied the roles of PIM1 in established T-lymphoma cell lines Jurkat and HUT-78. CCK-8 assay was conducted to evaluate cell survival and flow cytometry was performed to evaluate cell death of TCL cells. siRNAs were used to knockdown the expression of PIM1 and c-myc. qRT-PCR was used to evaluate the mRNA expression levels of c-myc and PIM1. Western blot analysis was used to evaluate the protein expression levels of PIM1, c-myc, STAT3, and phospho-STAT3. Doxorubicin was used to determine the effect of PIM1 on apoptosis. Our results showed that PIM1 expression was markedly enhanced and induced c-myc expression in TCL cells. Doxorubicin inhibited the expressions of c-myc and PIM1, and triggered the extrinsic cell death of TCLs by suppressing the JAK-STAT3 signaling pathway. Moreover, PIM1 silencing via siRNA suppressed c-myc expression, promoted the cell death of TCLs, and increased doxorubicin sensitivity. Conversely, PIM1 overexpression in TCL cells induced c-myc expression, suppressed TCL cell death, and promoted doxorubicin resistance. Collectively, our results demonstrate that PIM1 overexpression in TCLs participates in cancer cell protection from apoptosis and leads to doxorubicin resistance by inducing c-myc expression, indicating that PIM1 may be a promising target in TCL treatment.
Introduction
T-cell lymphomas (TCLs) are generated from the vicious hyperplasia of mature T lymphocytes and comprised 10%-15% of nonHodgkin lymphomas (NHLs) [1, 2] . In comparison to B-cell lymphomas (BCLs), TCLs are characterized by tumor aggression, poor clinical outcome, lack of treatment alternatives, and the absence of a cure [3, 4] . Consequently, novel biological treatment agents would be better for improving the clinical outcome of TCLs [5] . In addition to internal mutations, the external microenvironment is crucial for the pathogenesis of malignancy [6] . Malfunction of the cell death pathway is commonly associated with cancer development [7, 8] . In BCLs, genes counteracting intrinsic cell death, such as BCL-XL and BCL-2, are stimulated [9] . On the other hand, TCLs are often attributed to the disruption of extrinsic cell death [10, 11] . These findings indicate that modulating the cell death pathway can be a potential approach to treat TCLs.
PIM proteins are essential modulators in many hematologic and solid cancers [12, 13] . Overexpression of PIM1 is linked to the development and progression of several hematopoietic malignancies and prostate cancer [14] . PIM1 was originally identified as a preferential proviral integration site in Moloney murine leukemia virus-induced T-cell lymphomas and the first described member of the PIM family, which includes two other serine/threonine kinases PIM2 and PIM3 [15] . During embryonic development, PIM1 is highly and specifically expressed in liver, spleen and bone marrow in typical hematopoietic progenitors, neonatal heart, central nervous system at specific stages, and mammary gland [16] . In contrast, PIM1 is only slightly expressed in circulating granulocytes at the adult stage. The expression of PIM1 during development and its subsequent shut off in adult tissues suggest that its untimely overexpression may contribute to malignant transformation. Enforced expression of PIM1 in transgenic mice leads to enhanced lymphoproliferation and inhibition of apoptosis. As a proto-oncogene, PIM1 encodes a serinethreonine kinase, the expression of which is associated with the viability and growth of hematopoietic cells [17] . The expression of PIM1 is induced by multiple cytokines, including SCF, G-CSF, IFN-γ, GM-CSF, IL-2, -3, -6, -7, and prolactin. The effects of PIM1 on oncogenic processes are well known in comparison to those of other kinases in the PIM family, and its effects include modulating viability, cell cycle, resistance to drugs, transcription, and translation [14] . PIM1 overexpression is prevalent in human malignancies and is associated with poor clinical outcome in patients with leukemia [18, 19] . Consequently, PIM1 is a promising target for treating malignancies [20] . Furthermore, PIM1 promotes the progression of the cell cycle and suppresses cell death induced via the reduction of cytokines, Bax expression, and DNA-injuring agents [21] [22] [23] . In addition, PIM1 enhances c-myc transcriptional activity [24] . c-myc is dysregulated in many human cancers, especially in a large proportion of aggressive BCLs. The significance of c-myc dysregulation has also been recognized in TCLs. Studies in the Eμ-tTA/tetO-Myc conditional mouse model have demonstrated that the development of aggressive TCLs is a consequence of c-myc overexpression [23, 25] . Nevertheless, the specific effect of PIM1 on TCLs remains unclear.
In this study, we found that PIM1 and c-myc expressions were markedly enhanced in TCL cells. Doxorubicin inhibited the expression of c-myc and PIM1 and triggered the extrinsic cell death of TCLs by suppressing the JAK-STAT3 signaling pathway. Moreover, PIM1 silencing via siRNA suppressed c-myc expression, promoted the cell death of TCLs, and increased doxorubicin sensitivity. Conversely, PIM1 overexpression in TCL cells induced c-myc expression, suppressed TCL cell death, and promoted doxorubicin resistance (DR). Collectively, PIM1 overexpression in TCLs participates in cancer cell protection from apoptosis and leads to DR by inducing c-myc expression, indicating that PIM1 may be a promising target in TCL treatment.
Materials and Methods

Cells and reagents
Established T-lymphoma cell lines Jurkat and HUT-78 were purchased from the American Type Culture Collection (ATCC, Manassas, USA). The cells were cultured with RPMI 1640 medium (Invitrogen, Thermo Fisher Scientific, Carlsbad, USA) including 10% FBS (Invitrogen, Thermo Fisher Scientific) as well as 20 ng/ml IL-2 (R&D Systems, Cambridge, UK), as mentioned previously [26] . The peripheral blood mononuclear cells (PBMCs) of participants were separated via density gradient centrifugation with Separate-L (Muto Pure Chemical, Tokyo, Japan) and divided into CD4-, CD8-, CD19-, or CD56-positive proportions via magnetic beads conjugated to antibodies (IMag Human CD4, CD8, and CD56 Particles-DM; BD Biosciences, Sparks, USA). Doxorubicin was acquired from Wako Pure Chemical Industries (Osaka, Japan).
Cell survival analysis
CCK-8 assay was conducted to evaluate cell survival. Briefly, at the preliminarily decided time point before the terminal stage of treatment, CCK-8 solution (100 μl; Dojindo Molecular Technologies, Kumamoto, Japan) was added to each well. The cells were incubated for 4 h at 37°C. A multi-well spectrophotometer (490 nm; Bio-Rad, Berkeley, USA) was used to measure the absorbance at 450 nm.
Cell death assay
Flow cytometry (FC) was performed to evaluate cell death. Cold PBS was used to wash the obtained cells twice. Subsequently, the supernatant was discarded after centrifugation for 5 min at 100 rpm. The pellet was resuspended with binding buffer. Propidium iodide (PI) and FITC-Annexin V (Becton-Dickinson, Franklin Lakes, USA) were added, and the mixture was incubated for 10 min at room temperature. Fluorescence signals were assessed using a FACScan flow cytometer (Becton-Dickinson). The rate of cell death was calculated using FlowJo software version 7.6 (Tree Star, Ashland, USA).
Knockdown of PIM1 or c-myc via siRNA PIM1 siRNA (target sequence: 5′-GGUGUGUGGAGAUAUUCCU TT-3′) and control siRNA (target sequence: 5′-UUCUCCGAACGU GUCACGUTT-3′), and c-Myc siRNA (target sequence: 5′-AACGUUA GCUUCACCAACAUU-3′) and control siRNA (target sequence: 5′-AAUUCUCCGAACGUGUCACGU-3′) (100 nM; Santa Cruz Biotechnology, Paso Robles, USA) were transiently transfected with RNAiFect Transfection Reagent (Qiagen, Hilden, Germany). After 6 h of incubation at 37°C, the admixture was removed. Cells were incubated for an additional 24 h with RPMI 1640 medium containing 0.5% fetal serum prior to activation.
Cell transfection
After a confluence of 70%-80% was reached, cells were transfected with 1 μg of full-length pcDNA3.1-PIM1 (Addgene, Cambridge, USA) or pcDNA3.1 empty vector (Addgene) in Opti-MEM (Gibco, Grand Island, USA) using X-tremeGENE HP DNA Transfection Reagent (Roche, Rotkreuz, Switzerland). After incubation for 6 h at 37°C, the mixture was removed. Then, cells were incubated for an additional 24 h with medium containing 0.5% fetal serum prior to activation.
Quantitative reverse transcription PCR
Total RNA was obtained from the cultivated cells using TRIzol reagent (Invitrogen, Carlsbad, USA). Subsequently, quantitative reverse transcription PCR (qRT-PCR) was conducted using the Takara PrimeScript RT Reagent kit (Takara, Kyoto, Japan) with the following conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, followed by a hold at 4°C. The ABI 7300 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) and the QuantiTect SYBR Green PCR kit (Qiagen) were used for evaluation. GAPDH served as an internal reference. The primers (Applied Biosystems) used were as follows: c-myc forward primer 5′-ATGCCCCTCAACGTTAGCTT-3′ and reverse primer 5′-GAGAAGCCGCTCCACATAC-3′; PIM1 forward primer 5′-TCAA GCACGTGGAGAAGGAC-3′ and reverse primer 5′-CGAGCTCA CCTTCTTCAGCA-3′; GAPDH forward primer 5′-CAAAAGGGT CATCTCC-3′ and reverse primer 5′-CCCCAGCATCAAAGGTG-3′.
Western blot analysis
Cells (5 × 10 6 ) were harvested, washed with ice-cold PBS, and then lysed and sonicated in 0.5 ml lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium orthovanadate (Na 3 VO 4 ), 1 μg/ml leupeptin, and 1 mM PMSF. Lysis buffer (Beyotime, Beijing, China) was used for the homogenization of lysates. The Bradford assay (Bio-Rad) was used to quantify proteins. Proteins were analyzed with gradient (4%-12%) SDS-PAGE. Tris-HCl polyacrylamide gels (8%-15%; Bio-Rad) were used to isolate proteins before they were transferred to a PVDF membrane (Millipore, Bedford, USA). After being blocked with 5% BSA, the blots were incubated overnight with specific primary antibodies against STAT3 (1:1000), phospho-STAT3 (1:2000), JAK (1:1000), phospho-JAK (1:1000), c-myc (1:1000), and β-actin (1:3000) in TBST at 4°C, followed by incubation with HRP-conjugated secondary antibodies (1:5000). All antibodies were from Cell Signaling Technology (Beverly, USA). Finally, the Enhanced Chemiluminescence PLUS (ECL-PLUS) detection kit (Pierce, Rockford, USA) was used to assess immunoreactive bands, which were then analyzed with the Omega 16ic Chemiluminescence Imaging System (UltraLum, Claremont, USA).
Statistical analysis
The results are presented as the mean ± SEM. ANOVA and Tukey's post-hoc test were conducted to evaluate the differences among distinct treatment groups. A value of P < 0.05 was regarded as significant.
Results
PIM1 expression was elevated in TCL cells
Jurkat cells and HUT-78 cells were used to assess PIM1 expression and the expression of downstream c-myc [27] . PIM1 expression was first examined in these TCL cells with qRT-PCR. PIM1 transcription was markedly increased in HUT-78 and Jurkat cells compared with that in PBMCs as shown in Fig. 1A . Consistent with these findings, the expression of downstream c-myc was enhanced in the HUT-78 and Jurkat cells compared with that in PBMCs (Fig. 1A) . These results indicated that TCL cells highly express PIM1 and c-myc.
Doxorubicin enhanced apoptosis and suppressed JAK-STAT3-PIM1-c-myc pathway in TCL cells
In order to investigate the effect of PIM1 on apoptosis triggered by doxorubicin, we examined the expression of PIM1 by western blot analysis. Doxorubicin supplementation markedly impaired the expression of PIM1 and c-myc proteins in HUT-78 cells ( Fig. 2A-C) . The JAK-STAT3 signaling pathway was found to play an important role in modulating the expression of PIM1 [35] . Our study revealed that doxorubicin suppressed the phosphorylation of STAT3 and JAK in HUT-78 cells (Fig. 2D,E) , decreased cell viability (Fig. 2F) , and enhanced apoptosis (Fig. 2G) . These findings indicated that doxorubicin promoted cell death and inhibited JAK-STAT3-PIM1-cmyc signaling pathway in TCL cells.
PIM1 knockdown promoted doxorubicin-triggered apoptosis in TCL cells
In order to determine the effect of PIM1 on resistance to doxorubicin in TCLs, we knocked down the PIM1 expression using siRNA specific to PIM1 (Fig. 3A,B) . Knockdown of PIM1 impaired the c-myc expression, as shown in Fig. 3C . Moreover, knockdown of PIM1 promoted cell viability inhibition triggered by doxorubicin in HUT-78 cells (Fig. 3D) , indicating that PIM1 inhibited the cell viability inhibition triggered by doxorubicin in TCLs. Additionally, cell apoptosis triggered by doxorubicin was more significant in PIM1-siRNA-transfected cells than in control cells (Fig. 3E) . These findings indicated that PIM1 may directly contribute to DR in TCLs. 
PIM1 overexpression reduced doxorubicin-triggered apoptosis in TCL cells
Subsequently, we investigated if PIM1 directly lead to the resistance of TCL cells to chemotherapy by PIM1 overexpression. Transfection of PIM1 cDNA significantly increased the PIM1 expression in HUT-78 cells (Fig. 4A,B) . PIM1 overexpression also promoted the expression of c-myc, as shown in Fig. 4A ,C. The cell viability inhibition triggered by doxorubicin was reversed in PIM1 overexpression cells than in control cells (Fig. 4D) . PIM1 overexpression noticeably reduced the cell apoptosis triggered by doxorubicin in HUT-78 cells (Fig. 4E) . These findings demonstrated that PIM1 could promote DR in TCL cells.
c-myc knockdown impaired DR conferred by PIM1 overexpression in TCL cells
As PIM1 overexpression was accompanied by the induced expression of c-myc, we hypothesized that c-myc could play a role in this process. We therefore decreased the expression of c-myc using siRNA specific to c-myc (Fig. 5A,B) . Knockdown of c-myc had no effect on cell apoptosis (Fig. 5C) . The overexpression of PIM1 impaired apoptosis triggered by doxorubicin, and the knockdown of c-myc eliminated this effect in HUT-78 cells, as shown in Fig. 5D . Knockdown of c-myc promoted cell death triggered by doxorubicin and restored doxorubicin sensitivity in HUT-78 cells (Fig. 5E) . The results indicated that c-myc could modulate DR triggered by PIM1 overexpression in TCL cells.
Discussion
In this study, we demonstrated that TCL cells were characterized by an elevated concentration of PIM1 protein compared with PBMCs.
Additionally, we discovered that inhibiting PIM1 with siRNA promoted doxorubicin-triggered apoptosis in TCL cells. PIM1 overexpression reduced doxorubicin-triggered apoptosis, which was eliminated by the knockdown of c-myc in TCL cells. The findings indicated that PIM1 overexpression could lead to DR in TCL cells through c-myc (Fig. 6) .
As a serine/threonine kinase, PIM1 can enhance cell viability and proliferation and suppress cell death [24, 28] . Our study provides novel findings related to PIM1 in TCL cells. First, we discovered that PIM1 expression was markedly elevated in TCL cells. Although it is known that various mitogens and cytokines elevate PIM1 concentration in hematopoietic cells [29, 30] , it is unclear how PIM1 expression is modulated. Previous studies have demonstrated that stimulation of NF-кB can promote PIM1 expression in B lymphocytes [31] . In our study, JAK-STAT3 was found to participate in the modulation of PIM1 expression. As a cytoplasmic transcription factor, STAT3 is stimulated via the phosphorylation of tyrosine. STAT3 stimulation occurs in response to cytokines, agonists, dimerization-modulating growth factors, nuclear translocation, as well as the DNA binding of STAT3, which modulates gene expression. STAT3 activates various proteins and transcription factors, all of which participate in regulating proliferation and resistance to cell death [32] [33] [34] . Owing to the ability of PIM1 to promote proliferation and counteract cell death, it can potentially act as an essential signal downstream of STAT3. Doxorubicin suppresses JAK-STAT3 stimulation, which is related to the impaired expression of PIM1. These findings indicated that PIM1 could serve as a downstream target of STAT3 in TCL cells. Our study is in agreement with a previous study on the pulmonary vasculature of congenital diaphragmatic hernia triggered by nitrofen [35] . TLCs are frequently resistant to traditional chemotherapy drugs including doxorubicin [36, 37] . However, the mechanism of chemotherapy resistance remains unclear. Emerging evidence suggests that the expression of P-glycoprotein leads to chemotherapy resistance in T-cell lymphoproliferative diseases with EBV [38] . The findings in our study revealed that inhibition of the expression of PIM1 promoted apoptosis triggered by doxorubicin in TCL cells. On the contrary, PIM1 overexpression reduced apoptosis triggered by doxorubicin in TCL cells. Moreover, our study revealed that knockdown of PIM1 impaired c-myc expression, and PIM1 overexpression promoted the expression of c-myc in TCL cells. Increasing evidence shows that c-myc is essential for resistance to chemotherapy [39, 40] . Here, knockdown of c-myc eliminated DR triggered by PIM1 overexpression and restored doxorubicin sensitivity in TCL cells. Our findings suggest that PIM1 expression may lead to DR via upregulation of c-myc expression.
In conclusion, TCL cells are characterized by the functional expression of PIM1, which promotes the expression of c-myc and can lead to chemotherapy resistance. Our study suggests that PIM1 overexpression results in DR through c-myc. Therefore, PIM1 may serve as a promising target to overcome chemotherapy resistance in TCLs. Results are presented as the mean ± SEM of three independent experiments. *P < 0.05 and # P < 0.05. Figure 6 . Overview of the contribution of PIM1 to doxorubicin resistance via c-myc In TCL cells, the over-activated JAK-STAT3 pathway increased PIM1 expression and upregulated the expression of c-myc, which suppressed apoptosis and eventually led to doxorubicin resistance.
